



Janet Xiao

Partner, Morrison & Foerster
Palo Alto
(650) 813-5736
jxiao@mofo.com

Dr. Janet (Jian) Xiao is a partner in Morrison & Foerster's Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning.

Dr. Xiao has significant experience in developing and strengthening her clients' complex patent portfolios to maximize their commercial value and success. She has been working with Abraxis BioScience, a nanotechnology-based pharmaceutical company, since 2005 to develop a strong patent portfolio to protect its proprietary *Nab*TM technology and its leading anticancer drug, Abraxane®. The patent portfolio was a major component of the valuation underlying Abraxis' \$2.9 billion acquisition by Celgene in 2010, and Dr. Xiao continues to advise Celgene on the Abraxis patent portfolio after the acquisition. Dr. Xiao has worked with Taligen Therapeutics, a biotech company developing biologic and antibody products, since its inception in 2004 to build a strong patent portfolio. Her work has led to Taligen's successful \$65 million series B financing in 2008 and its \$111 million acquisition by Alexion Pharmaceuticals in 2011.

Dr. Xiao also advises biopharmaceutical companies such as Genentech and research institutions such as University of California on patent matters relating to various technologies including antibody therapeutics, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals. She also represents many start-up biopharmaceutical companies to help them build a strong IP position from inception.

In addition to patent prosecution and patent portfolio management, Dr. Xiao also helps her clients devise strategies in the events of legal challenges by third party competitors or *vice versa*. She is often engaged in third party patent challenges, such as *ex parte* reexamination, *inter parte* reexamination, patent opposition, and patent litigation. She also prepares legal opinions on patent validity and freedom to operate, and conducts IP due diligence reviews for business transactions.

Dr. Xiao is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China. She is frequently called upon to advise clients on IP issues relating to US/China cross-border transactions and operations in China. She is also frequently invited to speak on IP issues both in the U.S. and in China.

Dr. Xiao received her bachelor's degree from Nanjing University, attended the Chinese Academy of Sciences where she earned her master's degree and the University of California, Los Angeles for her Ph.D before graduating from the University of California, Berkeley School of Law.

For a list of Dr Xiao's past and future speaking engagements please click [here](#).



肖荐博士

美富律师事务所合伙人
帕洛阿尔托办事处
电话: (650) 813-5736
电子邮件: jxiao@mofo.com

肖荐博士 (Janet Xiao) 是美富律师事务所生命科学业务组的合伙人, 常驻帕洛阿尔托办事处。她多年致力于为生物技术和制药行业的客户处理其在全球范围内的专利申请、专利组合管理和战略策划事宜。

肖博士可帮客户开发和强化复杂专利组合, 以将客户专利组合的商业价值和功效最大化。在此方面, 肖博士拥有非常丰富的经验。从 2005 年起, 她便一直与纳米技术制药公司阿博利斯科学公司 (Abraxis BioScience) 合作开发强大的专利组合, 以保护其专有的 *nab*TM 技术和领先的抗癌药物 *Abraxane*[®]。在 2010 年 Celgene 公司收购阿博利斯公司时, 该专利组合构成阿博利斯公司 29 亿美元估值的主要组成部分。收购完成之后, 肖博士继续就阿博利斯专利组合事宜向 Celgene 提供法律咨询。自从事生物及抗体产品开发的生物技术公司 Taligen Therapeutics 成立伊始, 肖博士就与该公司合作建立强大的专利组合。在她的帮助下, Taligen 公司于 2008 年成功进行了 6,500 亿美元的 B 系列融资, 并于 2011 年被 Alexion 制药公司以 1.11 亿美元的价格收购。

肖博士还就专利事宜向基因泰克 (Genentech) 等生物制药公司和加州大学等研究机构提供法律咨询, 所涉及的技术包括抗体疗法、个性化医学、药物传输系统、药物筛查平台、诊断和营养学等。她还帮许多新成立的生物制药公司从头打造强大的知识产权地位。

除专利申请和专利组合管理以外, 肖博士还可帮客户设法应对由第三方竞争者提出的法律质疑, 或对第三方竞争者提出法律质疑。她经常处理第三方专利质疑事宜, 如单方面复审、双方复审、专利异议和专利诉讼。她还可就专利有效性和自由使用等问题提供法律意见书, 并对商业交易进行知识产权尽职调查。

肖博士既有熟练的全球战略性知识产权管理技能, 又了解中国独特的知识产权问题。这样的律师人数极少。她经常被聘用就涉及中/美跨境交易和中国境内经营的知识产权问题向客户提供法律咨询。她还经常被邀请在美国和中国就知识产权问题发表演讲。

肖博士曾获得南京大学学士学位、中国科学院生物物理研究所理学硕士学位以及美国加州大学洛杉矶分校博士学位。她在加州大学伯克利分校法学院获得法学博士学位。